Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

FDA approves Madrigal Therapeutics’ NASH drug

by Sarah Braner
March 25, 2024 | A version of this story appeared in Volume 102, Issue 9

 

The chemical structure of resmetirom.


The US Food and Drug Administration has approved Madrigal Therapeutics’ Rezdiffra (resmetirom) to treat patients with noncirrhotic nonalcoholic steatohepatitis (NASH) who also have moderate to advanced liver fibrosis. NASH describes a condition—not caused by alcohol abuse—in which fatty tissue accumulates in the liver. It is a leading cause of liver transplants in people 65 and older. Madrigal says Rezdiffra is the first medication approved to treat NASH.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.